Pathalys inks de­vel­op­ment deal with Abing­worth com­pa­ny, rais­ing $150M

Pathalys Phar­ma, a pri­vate biotech co-found­ed by Japan­ese VC Catalys Pa­cif­ic and DaVi­ta Ven­ture Group in late 2020 to fo­cus on chron­ic kid­ney dis­ease, an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER